An update on pharmacotherapy for recurrent depression in 2022.

Introduction: Major depressive disorder remains a major challenge due to its biopsychosocial burden with increased morbidity and mortality. Despite successful treatment options for the acute episode, recurrence rates are high, on average four times in a life span.

Areas Covered: Both pharmacological as non-pharmacological evidence-based therapeutic options to prevent and treat recurrent depression are discussed.